Goldman Sachs’ Numantec Deal Shows What Medical Device Investors Want In 2026

According to Reuters, Goldman Sachs Alternatives has agreed to acquire a controlling interest in Numantec from White Bridge Investments. Numantec develops and manufactures infusion, vascular-access, drug-delivery, and other medical products. The company employs approximately 600 people across seven manufacturing facilities in Europe and the United States. Its customers operate in clinical markets with steady demand and high quality requirements. 

The transaction reportedly values the Italian medical device group Numantec at approximately €700 million ($795,931,500) and is expected to close in the fourth quarter of 2026. 

What’s interesting about this particular deal for medical device marketers and owners is that Goldman Sachs is not acquiring a company built around one device. Instead, it is acquiring a medical technology platform assembled through multiple acquisitions. White Bridge began building Numantec's business through its 2021 investment in Delta Med, an Italian vascular-access device manufacturer. Numantec later acquired Health Line International, which gave the group a stronger position in the United States. 

White Bridge built Numantec by acquiring companies that added products, manufacturing capacity, and access to new markets. Numantec's business model does not depend on the performance of any one device or region. Reuters characterized the transaction as “a bet on a company with steady revenue during macroeconomic uncertainty.”

The Numantic deal is not the only deal that reflects this investment logic. In fact, it shows an emerging trend across recent medical device investments. 

Recent Deals Show A Broader Investment Pattern

In July 2026, KKR launched Allyntra as an engineered-solutions platform for medical technology and other precision industries. The platform combines companies that provide product design, prototyping, precision components, micro-manufacturing, and other specialized capabilities. It gives KKR exposure to the infrastructure required to develop and manufacture complex medical products. 

The Allyntra deal shows that investors are looking beyond finished devices. They are also investing in the specialized engineering and manufacturing systems behind those devices. These capabilities can support several product categories, customers, and end markets.

Another deal from early in 2026 also shows the value of differentiated products that already have commercial distribution and clinical adoption.

In April, American Industrial Partners announced plans to acquire Avanos Medical for approximately $1.27 billion, a 72.1% premium over the company’s prior closing price. Avanos sells enteral-feeding products and non-opioid pain-management technologies, including its Coolief radiofrequency treatment system. Avanos gives American Industrial Partners established products in durable clinical markets.

A larger example of this trend is seen with the April 2026 acquisition of Hologic by Blackstone and TPG for $18.3 billion. Hologic brought the buyers an established position in breast-health diagnostics, gynecologic surgery, and molecular diagnostics. The transaction was one of the largest medical device deals in almost two decades. It shows the premium investors can place on category leadership, portfolio depth, and global distribution.

Blackstone and TPG are now reportedly seeking more than $4 billion for Hologic’s surgical division. The potential sale shows another part of the investment strategy. Buyers can acquire a large platform, separate its business units, and assign individual values to specialized portfolios. 

Montagu and Kohlberg followed a similar logic when they agreed to acquire Teleflex Medical OEM for $1.5 billion. The business designs and manufactures custom medical devices, catheters, sutures, fibers, and precision components. It is expected to operate as an independent company after the transaction closes. 

Beyond its own internal product line, Teleflex Medical OEM is valuable because it has the capabilities to support other medical device companies. It provides technical expertise, manufacturing infrastructure, and development support across multiple product categories. So investors are purchasing a position within the medical device supply chain rather than relying on the success of one branded product.

Growth investors are also targeting companies with validated technology and a clear expansion path. In June 2026, TA Associates announced a strategic growth investment in AIRS Medical. The company develops AI-powered MRI products, including software designed to improve image quality and reduce scan times.

Now, AIRS Medical is not a large buyout or carve-out. However, the underlying investment logic is the same as with Numantec, Hologic, and Teleflex Medical OEM. Medical device investors are choosing companies with diverse capabilities, proof of market, and clear device adoption pathways.

Three Investment Trends Connect These Deals

The recent medical device investment transactions point to three clear trends:

1. Investors Want Platforms Rather Than Isolated Products

Numantec was built through acquisitions, Hologic combines several women’s health businesses, and Teleflex Medical OEM supports multiple customers and product lines. Each of these platforms gives an investor more than one source of value. It can support new products, enter adjacent categories, and expand geographically.

PwC reports that med tech deal activity remained near its highest level in more than a decade during the first half of 2026. The firm expects continued activity around sustainable growth, breakthrough technologies, and ecosystem capabilities. Medical device companies seeking investment should therefore explain how their existing product creates a larger opportunity. Investors need to understand what can be added around the core technology.

2. Specialized Capabilities Have Become Investable Assets

KKR’s Allyntra platform and the Teleflex Medical OEM carve-out show strong interest in specialized engineering and manufacturing. These businesses possess technical knowledge, quality systems, and production capabilities that are difficult to reproduce. Numantec offers a related advantage. Its seven facilities provide an operating base for European and U.S. expansion. The investor is not starting with a license and a product concept. It is acquiring the ability to manufacture and distribute at scale.

The investment in specialized capabilities and medical device value does not reside only in intellectual property. Production processes, regulatory systems, and product-development expertise also provide value. Further, investors consider companies with strong supplier and clinical relationships as highly valuable. 

3. Investors Want A Visible Path To Commercial Value

Avanos offers established revenue from pain-management and enteral-feeding products, Hologic has category leadership in women’s health, and AIRS Medical combines AI technology with a defined clinical application and global growth strategy. The common factor among these three deals is not the novelty. Instead, it is the obvious connection between the technology and an identifiable commercial outcome.

EY reported that MedTech deal volume increased in 2025 while average deal sizes also rose. The market research firm attributed this activity to demand for best-in-class innovations that were ready or close to commercial launch. EY also found that 84% of surveyed life sciences CEOs expected investors to increase their scrutiny of returns from capital-allocation decisions. Deloitte reached a similar conclusion in its midyear 2026 life sciences analysis. Investor questions increasingly focus on revenue outlook, launch execution, demand, margins, costs, and market share. Those questions require operational and commercial evidence, not broad statements about innovation. 

What This Means For Medical Device Marketers

An investor does not assess a medical device company through product messaging alone. They also assess the commercial system surrounding the product. So your marketing must explain where the company fits within the market ecosystem. It must show why the opportunity can support growth, consolidation, or strategic expansion. Medical device marketers should be prepared to communicate:

• The size and structure of the addressable market

• The unmet clinical and/or economic need

• The company’s position within the care pathway

• The evidence supporting adoption

• The revenue model and purchasing cycle

• The reimbursement and regulatory position

• The manufacturing and supply-chain advantage

• The opportunity for portfolio expansion

• The opportunity for geographic expansion

• The company’s value to strategic buyers or platform investors

These points must remain consistent across your investor presentations, technical content,  and sales materials. Conflicting numbers or vague claims weaken the investment case.

The Numantec deal provides a useful standard that marketers can use. An investor can quickly understand the company’s clinical categories, geographic presence, and expansion plan. Those facts create a clear value narrative that attracts investors. Smaller medical device companies may not have seven factories or a €700 million valuation. However, they still need to show how the current business can become more valuable.

Build Marketing Assets Around The Investment Thesis

A medical device company preparing to seek capital should build its communications around the questions an investor will ask. Here's what you need:

• An investor-positioning brief that defines the company’s category, differentiation, and growth thesis. It should give executives a common framework for discussing the opportunity.

• A market-opportunity report that documents the addressable market, customer demand drivers, and competitive environment. It should connect external market evidence to the company’s growth plan.

• An investor presentation to explain the clinical problem, market position, and use of capital. It should show how investment creates measurable value.

• Product and portfolio messaging to establish how each technology contributes to the larger business.

• Technical explainers that translate complex engineering and clinical information without weakening its accuracy. Investors need enough detail to understand the advantage and its defensibility.

• The company website should support investor diligence. It should clearly present the leadership team, technology and evidence, and market opportunity.

• Due-diligence content should organize the company’s regulatory, clinical, and operational evidence. It should reduce uncertainty before formal investor review begins.

Together, these marketing pieces will create the commercial narrative behind the investment case for your medical device company. 

Make The Investment Opportunity Clear

The recent Goldman Sachs investment in Numantec and other recent medical device acquisitions show investors want to see the complete value structure of the business. They need to understand what the company owns, where it can grow, and how capital changes its trajectory. When you connect each product, capability, and market opportunity to a larger growth strategy, investors can see how your medical device business becomes more valuable over time.

Borrowed Pen helps medical device companies turn clinical, technical, and market evidence into a clear investor-facing story. We’ll help you communicate the full value of your offer. Learn more about our medical device marketing services.